For medical device manufacturers selling products in the United States, FDA quality system requirements are a fundamental part of maintaining regulatory compliance. Historically, these requirements were commonly referred to as the Quality System Regulation (QSR) under 21 CFR Part 820.

The FDA’s updated quality management requirements have moved toward greater alignment with ISO 13485:2016. The Quality Management System Regulation (QMSR) became effective in February 2026, making this transition particularly important for organizations operating in the U.S. medical device market.

The underlying objective remains clear: manufacturers need a controlled, documented quality management system that consistently supports the safety and effectiveness of their devices.

Key areas include:

• Quality management processes
• Design and development controls
• Production and process controls
• Purchasing and supplier controls
• Corrective and preventive action
• Complaint handling
• Records and documentation
• Identification and traceability
• Management responsibility
• Quality audits
• Nonconforming product controls

Compliance is not simply about having procedures written in a quality manual. Companies must be able to demonstrate that their procedures are implemented, maintained, monitored, and supported by appropriate records.

This is where QSR FDA Compliance Solutions can provide valuable support. A structured compliance approach helps organizations identify weaknesses before they become inspection findings and establish processes that can withstand regulatory scrutiny.

What ISO 13485 Requires

ISO 13485 is an internationally recognized quality management standard specifically designed for organizations involved in medical devices and related services.

Rather than focusing exclusively on the expectations of one regulator, ISO 13485 provides a framework for establishing a quality management system appropriate for the medical device lifecycle.

The standard addresses areas such as:

• Quality management systems
• Documentation and records
• Management responsibility
• Resource management
• Product realization
• Risk-based processes
• Purchasing and supplier management
• Production controls
• Monitoring and measurement
• Nonconforming products
• Corrective and preventive action
• Internal audits
• Continuous quality-system oversight

ISO 13485 can be particularly valuable for companies operating internationally because it provides a common framework recognized across many medical device markets.

However, certification to ISO 13485 does not automatically mean that every FDA requirement is satisfied. Companies must understand the regulatory expectations applicable to their products, activities, and markets.

Key Differences Between QSR and ISO 13485

The relationship between FDA requirements and ISO 13485 has become much closer with the FDA’s implementation of QMSR. Even so, organizations should not assume that compliance can be achieved simply by obtaining an ISO certificate.

One important difference historically has been the regulatory context. FDA requirements are legally enforceable requirements for companies subject to U.S. medical device regulations, while ISO 13485 is a consensus-based international quality management standard that organizations may use for certification and market access.

Another difference involves how requirements are interpreted and enforced. FDA inspections evaluate whether an organization complies with applicable federal requirements and whether its actual practices support device quality and patient safety.

ISO 13485 audits, meanwhile, evaluate conformity with the standard and the organization’s established quality management system.

The practical lesson is that medical device companies need to look beyond certificates and documented procedures. They should examine how their systems operate in real-world conditions.

For example, a supplier may have an approved status in a database, but an auditor may want to understand how the supplier was qualified, how performance is monitored, how changes are controlled, and what happens when a supplier fails to meet expectations.

This makes Internal and Supplier Audits an important component of an effective quality strategy.

Which Standard Applies to Your Company?

The answer depends on your business activities, products, markets, and regulatory obligations.

If your company manufactures medical devices for the U.S. market, FDA requirements are critical. If your organization operates internationally or wants to demonstrate conformity with an internationally recognized medical device quality management framework, ISO 13485 may also be highly valuable.

For many organizations, the most practical approach is not choosing one standard over the other. Instead, companies can develop a quality system that integrates applicable FDA requirements with ISO 13485 principles.

This integrated strategy can reduce duplication, improve consistency, and make quality processes easier to manage across multiple markets.

Companies should consider their:

• Product classification
• Manufacturing activities
• Geographic markets
• Supplier network
• Design and development responsibilities
• Regulatory submission obligations
• Existing quality management system
• Customer and market requirements
• Inspection history and compliance risks

A gap assessment can help determine where current processes align with applicable requirements and where additional controls may be necessary.

How to Achieve Dual Compliance

Building a strong quality system starts with understanding the organization’s current state.

The first step is generally a structured gap assessment. Review existing procedures, records, responsibilities, training programs, supplier controls, audit processes, complaint systems, CAPA activities, and design controls.

Next, identify areas where requirements overlap. Rather than maintaining separate systems for every requirement, organizations can often develop integrated processes that address multiple expectations.

For example, a supplier management program can incorporate qualification, risk assessment, performance monitoring, periodic evaluation, change management, and audit requirements within one controlled framework.

Internal audits should then test whether these processes actually work.

Effective Internal and Supplier Audits should go beyond checking whether a document exists. Auditors should examine objective evidence, interview personnel, review records, evaluate implementation, and determine whether controls are producing the intended results.

Training is another critical element. Employees need to understand not only what a procedure says but also why the process matters and how their responsibilities contribute to product quality and regulatory compliance.

Finally, organizations should establish a continuous improvement cycle. Findings from audits, complaints, CAPA investigations, supplier performance, deviations, and management reviews should feed into ongoing quality-system improvements.

Common QSR Inspection Findings in 2026

As FDA expectations continue to evolve under QMSR, medical device companies should pay close attention to weaknesses that can create compliance concerns.

Common areas of inspection attention include:

Inadequate Documentation and Records

Missing, incomplete, inconsistent, or poorly controlled records can make it difficult to demonstrate that processes were properly performed.

Weak CAPA Systems

Corrective and preventive action programs should address root causes rather than simply correcting individual problems. Investigations should be supported by evidence and effectiveness checks.

Insufficient Supplier Controls

Organizations remain responsible for ensuring that purchased products and services meet applicable requirements. Poor supplier qualification, monitoring, or documentation can create significant quality risks.

Ineffective Internal Audits

An internal audit program should identify meaningful quality-system weaknesses before an external auditor or FDA investigator does. Audits that are overly superficial may provide a false sense of compliance.

Inadequate Design Controls

For companies responsible for device design and development, documentation should demonstrate that design requirements, verification, validation, changes, and related activities are appropriately controlled.

Poor Change Management

Uncontrolled changes to processes, software, equipment, suppliers, or specifications can introduce quality and regulatory risks.

Insufficient Inspection Preparation

Being technically compliant is important, but employees must also understand how to respond accurately and consistently during an inspection. This is why FDA Inspection Readiness should be treated as an ongoing organizational capability rather than a last-minute preparation exercise.

How BioNetwork Consulting Can Help

BioNetwork Consulting supports life sciences organizations with regulatory, quality, compliance, and specialized talent needs. Its experience across pharmaceutical, biotechnology, and medical device environments allows organizations to address complex quality challenges with practical strategies.

Its compliance-focused services can support organizations working toward stronger validation, quality assurance, audit preparation, and regulatory readiness. The company’s specialized approach combines industry knowledge with practical guidance designed around each client’s operational requirements.

For medical device organizations, this type of support can be valuable when preparing for regulatory inspections, reviewing quality systems, strengthening audit programs, or identifying compliance gaps before they become larger problems.

The goal is straightforward: create systems that are not only documented but actually work.

FAQ

1. Is ISO 13485 the same as FDA QSR?

No. They have historically been separate frameworks, although the FDA’s QMSR implementation has brought U.S. medical device quality requirements into much closer alignment with ISO 13485:2016. Companies still need to understand and meet the FDA requirements applicable to their operations.

2. Does ISO 13485 certification guarantee FDA compliance?

No. ISO 13485 certification does not by itself guarantee compliance with every FDA requirement. Organizations must evaluate their specific FDA obligations and ensure their quality system addresses them.

3. Why are internal audits important for FDA inspection readiness?

Internal audits provide an opportunity to identify weaknesses before an FDA inspection or external assessment. Effective audits can uncover documentation gaps, process failures, training issues, supplier concerns, and ineffective corrective actions.

4. What are supplier audits?

Supplier audits evaluate whether suppliers consistently meet established quality and regulatory requirements. Depending on supplier risk, audits may review quality systems, manufacturing controls, records, change management, CAPA, and other relevant processes.

5. How often should a medical device company conduct internal audits?

There is no single frequency appropriate for every organization. Audit schedules should reflect regulatory requirements, organizational risk, process importance, previous findings, changes, and supplier or operational performance.

6. What is FDA Inspection Readiness?

FDA Inspection Readiness means maintaining the systems, records, personnel knowledge, and processes necessary to respond effectively when FDA investigators evaluate an organization’s compliance. It should be an ongoing activity rather than something started immediately before an inspection.

7. Can one quality system support both FDA and ISO 13485 requirements?

Yes. Organizations can develop an integrated quality management system that addresses applicable FDA requirements and ISO 13485 expectations. The exact structure should be based on the organization’s products, activities, markets, and regulatory responsibilities.

8. How can QSR FDA Compliance Solutions help medical device companies?

QSR FDA Compliance Solutions can help organizations evaluate quality-system gaps, strengthen procedures, improve documentation, prepare for inspections, enhance audit programs, and establish processes aligned with applicable regulatory expectations.

Moving Forward With Greater Compliance Confidence

For medical device companies, quality compliance is more than a regulatory obligation. It is an essential part of protecting patients, maintaining product quality, supporting market access, and building long-term business credibility.

The transition toward QMSR in 2026 makes it especially important for organizations to understand how FDA requirements and ISO 13485 work together. Companies that proactively evaluate their quality systems, strengthen Internal and Supplier Audits, and invest in FDA Inspection Readiness can approach regulatory scrutiny with greater confidence.

BioNetwork Consulting brings together life sciences expertise, regulatory knowledge, quality support, and specialized talent to help organizations navigate this complex environment. With the right strategy, compliance does not have to slow innovation. Instead, a well-designed quality system can provide the foundation for safer products, stronger operations, and more sustainable growth.